Statyny - opis, przeciwwskazania, efekty uboczne... naturalne statyny

The origins of statin research trace back to 1976, when a team of scientists led by Japanese biochemist Professor Akira Endo successfully isolated the first statin compound from the fungal culture *Penicillium citrinum*. In contemporary clinical practice, these agents constitute a cornerstone of pharmacotherapy for hypercholesterolemia and are routinely prescribed to individuals with elevated low-density lipoprotein (LDL) cholesterol levels. Statins belong to the class of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, an enzyme that plays a pivotal role in the endogenous biosynthesis of cholesterol within hepatocytes. By reversibly inhibiting this enzyme, statins initiate a cascade of metabolic responses: the intracellular cholesterol concentration diminishes, which in turn upregulates the expression of LDL receptors on the surface of liver cells. This process enhances the clearance of LDL particles from circulation, ultimately reducing their plasma concentrations. Among the most frequently prescribed statins are atorvastatin, rosuvastatin, simvastatin, and lovastatin. Their administration not only yields favorable modifications in lipid profiles—including reductions in total cholesterol, LDL fractions, and triglycerides alongside a modest increase in high-density lipoprotein (HDL) cholesterol—but also exerts a spectrum of non-lipid-related (pleiotropic) effects. Clinical evidence supports their role in stabilizing atherosclerotic plaques, attenuating inflammatory biomarkers (such as C-reactive protein), improving endothelial function, and modulating thrombogenic processes. Emerging data further suggest potential neuroprotective benefits (reduced risk of Alzheimer’s disease in older adults), enhanced glycemic control in patients with type 2 diabetes, preventive effects against cataract formation, and a blood pressure-lowering capacity.

The administration of HMG-CoA reductase inhibitors—commonly referred to as statins—is categorically prohibited in patients presenting with a spectrum of severe hepatic impairments, including: actively progressing acute viral hepatitis, chronic alcohol-induced parenchymal liver injury, decompensated cirrhosis with synthetic dysfunction, and fulminant hepatic failure characterized by abrupt organ collapse. Furthermore, due to the potential for adverse outcomes, statin therapy necessitates heightened caution in individuals with compromised renal function (particularly those with creatinine clearance <30 mL/min) and in pregnant women, where the therapeutic benefits must be meticulously balanced against fetal safety concerns.

While statins are widely recognized as well-tolerated lipid-lowering medications, their use may be associated with a spectrum of adverse reactions. The most frequently reported side effects involve the gastrointestinal system, with patients experiencing symptoms such as abdominal distension, nausea, constipation, and various dyspeptic complaints—including epigastric pain. Less commonly, individuals may report headaches, dizziness, alopecia, or sleep disturbances. Routine monitoring of hepatic enzyme levels is strongly advised, as approximately 1% of patients may exhibit elevated serum concentrations of these biomarkers. Additionally, clinical evidence highlights the potential for statin-induced abnormalities in striated muscle function, affecting both skeletal and cardiac muscle tissues. The predominant manifestations include muscle weakness (myopathy) and muscular pain (myalgia), with the latter affecting up to 7% of statin users, as documented in research conducted by Bruckert and colleagues.

Pharmacologically active lipid-lowering compounds can be categorized according to multiple structural and functional criteria. The primary distinction concerns their chemical form: certain statins exist as inactive prodrugs requiring enzymatic conversion to their bioactive forms (e.g., simvastatin), whereas others—such as pravastatin—are inherently active as hydroxy acid derivatives. A secondary classification considers physicochemical properties: hydrophilic statins (water-soluble) versus hydrophobic statins (water-insoluble). Another critical dimension is origin: natural, semisynthetic, and fully synthetic compounds. Natural statins, including lovastatin and compactin, are initially biosynthesized by strains of the fungus *Aspergillus terreus* under controlled fermentation conditions, followed by chemical modifications to yield semisynthetic derivatives like simvastatin or pravastatin. Statin pharmacotherapy extends beyond mere low-density lipoprotein (LDL) cholesterol reduction; these agents exhibit pleiotropic effects, including arterial blood pressure reduction, atherosclerotic plaque stabilization (thereby mitigating the risk of acute coronary events), and enhanced endothelial vascular function. While statins generally demonstrate a favorable safety profile, they may induce adverse effects such as dyspepsia, myalgia (muscle pain), or—rarely—rhabdomyolysis, necessitating biochemical monitoring throughout treatment.